Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment”

Virtual webinar scheduled for Thursday, May 4 at 8:00 am pacific / 11:00 am easternMeet with Atossa’s Founder and CEO, Steven Quay, M.D., Ph.D.Event is open to the public – registration available at...
March 22, 2023 16:05 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update

SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
March 21, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial

SEATTLE and SAN FRANCISCO, March 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...
March 15, 2023 09:25 ET | Source: Atossa Therapeutics, Inc.

Atossa to Present at the Sidoti Small-Cap Virtual Conference

SEATTLE, March 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
February 23, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
February 13, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen

SEATTLE, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
January 25, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Issues Letter to Shareholders

SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
December 07, 2022 08:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations

SEATTLE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
November 07, 2022 16:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on...
November 01, 2022 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy

SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc....

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right